isoxazoles has been researched along with Cholera Infantum in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Blackshear, CP; Burcham, A; Chinta, MS; Cui, L; Foster, DS; Gulati, GS; Gurtner, GC; Hu, MS; Januszyk, M; Jones, RE; Kin, CJ; King, ME; Lerbs, T; Longaker, MT; Manjunath, A; Marshall, CD; Mascharak, S; Moore, AL; Nguyen, A; Norton, JA; Ransom, RC; Salhotra, A; Shelton, AA; Titan, AL; Wernig, G | 1 |
| An, YM; Chung, MJ; Kim, E; Seo, JG; Shin, JH; Song, SC | 1 |
| Arung, W; Odimba, E; Tshilombo, F | 1 |
| Jones, PB; Lynskey, NV; White, DH | 1 |
| Kellner, H; Schiemann, U | 1 |
| Goldstein, JL; Kent, JD; Kivitz, AJ; Palmer, RC; Recker, DP; Verburg, KM | 1 |
| Benoit, V; de Leval, X; Dogné, JM; Frederich, M; Julémont, F; Pirotte, B | 1 |
| Fitzgerald, GA | 1 |
| Ohtahara, S; Yamatogi, Y | 2 |
| Dimitrova, P; Ivanovska, N | 1 |
| Ichiki, T; Kodama, R; Kuwasaki, E; Kuwata, M; Satoh, K; Sone, H; Yamamoto, N; Yamashita, K | 1 |
| Furukawa, H; Ichiki, T; Kodama, R; Kuwata, M; Nasu, Y; Satoh, K; Sone, H; Yamashita, K | 1 |
| Chang, YC; Falkson, G; Knuiman, MW; Pandya, KJ; Skeel, RT; Willson, JK; Wolter, JM | 1 |
2 review(s) available for isoxazoles and Cholera Infantum
| Article | Year |
|---|---|
[Gastrointestinal side effects in the therapy of rheumatologic diseases].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Etanercept; Gastrointestinal Diseases; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Methotrexate; Randomized Controlled Trials as Topic; Receptors, Tumor Necrosis Factor; Rheumatic Diseases; Stomach Ulcer; Sulfasalazine; Tumor Necrosis Factor-alpha | 2002 |
First and second generations of COX-2 selective inhibitors.
Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2004 |
2 trial(s) available for isoxazoles and Cholera Infantum
| Article | Year |
|---|---|
A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Humans; Intestinal Mucosa; Isoxazoles; Naproxen; Osteoarthritis; Pain; Risk Factors; Sulfonamides | 2003 |
Phase II clinical trial of acivicin in advanced breast cancer: an Eastern Cooperative Oncology Group Study.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Central Nervous System Diseases; Clinical Trials as Topic; Drug Evaluation; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Isoxazoles; Middle Aged; Neoplasm Metastasis; Oxazoles | 1986 |
11 other study(ies) available for isoxazoles and Cholera Infantum
| Article | Year |
|---|---|
Elucidating the fundamental fibrotic processes driving abdominal adhesion formation.
Topics: Animals; Benzophenones; Cells, Cultured; CRISPR-Cas Systems; Doxycycline; Fibroblasts; Fluorescent Antibody Technique; Gastrointestinal Diseases; Humans; Immunohistochemistry; Isoxazoles; Liposomes; Mice; NIH 3T3 Cells; Parabiosis; RNA, Messenger; Tamoxifen; Tissue Adhesions | 2020 |
Beneficial effects of a probiotic blend on gastrointestinal side effects induced by leflunomide and amlodipine in a rat model.
Topics: Amlodipine; Animals; Antihypertensive Agents; Antirheumatic Agents; Cytokines; Gastrointestinal Diseases; Gastrointestinal Microbiome; Isoxazoles; Leflunomide; Male; Probiotics; Rats, Sprague-Dawley; Treatment Outcome | 2017 |
[Parecoxib effects in the prevention of postoperative abdominal adhesions: randomized experimental study in rats].
Topics: Abdominal Wall; Animals; Cyclooxygenase 2 Inhibitors; Gastrointestinal Diseases; Injections, Intramuscular; Injections, Intraperitoneal; Isoxazoles; Male; Postoperative Complications; Random Allocation; Rats; Rats, Sprague-Dawley; Tissue Adhesions | 2015 |
Leflunomide use in New Zealand. A national prospective post-marketing study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Isoxazoles; Leflunomide; Male; Middle Aged; New Zealand; Product Surveillance, Postmarketing; Prospective Studies; Registries; Young Adult | 2009 |
Coxibs and cardiovascular disease.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Epoprostenol; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk; Sulfonamides; Sulfones; Thromboxane A2; United States; United States Food and Drug Administration | 2004 |
Safety of zonisamide therapy: prospective follow-up survey.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Incidence; Infant; Isoxazoles; Male; Mental Disorders; Middle Aged; Product Surveillance, Postmarketing; Zonisamide | 2004 |
Influence of leflunomide on gastrointestinal Candida albicans infection induced in naive and arthritic newborn mice.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Candida albicans; Candidiasis; Collagen; Colony Count, Microbial; Female; Gastrointestinal Diseases; Hypersensitivity, Delayed; Immunoglobulin G; Interferon-gamma; Interleukin-4; Isoxazoles; Leflunomide; Male; Mice; Mice, Inbred ICR; Spleen; Th1 Cells; Th2 Cells | 2006 |
Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Isoxazoles; Lactones; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones | 2006 |
Erratum to "Safety of zonisamide therapy: prospective follow-up survey.".
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Incidence; Infant; Isoxazoles; Male; Mental Disorders; Middle Aged; Product Surveillance, Postmarketing; Zonisamide | 2007 |
Acute toxicity tests of mofezolac (N-22) in mice and rats.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Female; Gastrointestinal Diseases; Injections, Intraperitoneal; Injections, Subcutaneous; Isoxazoles; Lethal Dose 50; Male; Mice; Mice, Inbred ICR; Rats; Rats, Inbred Strains | 1990 |
[Fifty two-week chronic oral toxicity study of mofezolac (N-22) in rats].
Topics: Administration, Oral; Anemia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Female; Gastrointestinal Diseases; Isoxazoles; Kidney Diseases; Liver; Male; Rats; Rats, Inbred Strains | 1990 |